U.S. health regulators recommended against use of Pfizer Inc?s pulmonary arterial hypertension (PAH) drug Revatio in children up to 17 years of age, saying it had a higher risk of death when taken in a high dose.
While the drug has never been approved for treatment of PAH in children, the U.S. Food and Drug Administration?s warning is against off-label use of the drug.
Revatio, which has the same active ingredient as Pfizer?s erectile dysfunction drug Viagra, is used to improve the ability to exercise in people with PAH - or High Blood Pressure in the vessels carrying blood to the lungs.
The FDA said the recommendation against the use of the drug is based on a recent clinical trial, and the Revatio drug label will carry the warning.
(Reporting by Prateek Kumar in Bangalore; Editing by Maju Samuel)
###
(Reuters)
Provided by ArmMed Media
| ?Comments | [ + Post Your Own ]? |
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
Source: http://www.health.am/ab/more/use-of-pfizers-revatio-in-children/
2011 nfl playoff schedule cowboys vs giants ndaa timberwolves weight watchers rawhide bigfoot
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.